Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02790138 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
A Phase 4 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 4
- Development phase
- 102
- Enrollment target
NCT02790138 is a Phase 4 study that has completed, run by Takeda. The registered enrollment target is 102 participants.
The verdict
NCT02790138, a Phase 4 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of vedolizumab intravenous (IV) and placebo in terms of the percentage of participants with chronic or recurrent pouchitis achieving clinically relevant remission.
Interventions
- DRUG Vedolizumab
- DRUG Ciprofloxacin
- DRUG Vedolizumab Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2016-10-12 |
| Est. Completion | 2021-02-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02790138
The ClinicalTrials.gov registry entry for NCT02790138 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vedolizumab is the first listed.
NCT02790138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02790138 about?
NCT02790138 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis". The purpose of this study is to compare the efficacy of vedolizumab intravenous (IV) and placebo in terms of the percentage of participants with chronic or recurrent pouchitis achieving clinically relevant remission.
What is the current status of trial NCT02790138?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 102 participants. The study started on 2016-10-12. Estimated completion is 2021-02-02.
What interventions are being tested in trial NCT02790138?
The interventions under investigation include: Vedolizumab (DRUG), Ciprofloxacin (DRUG), Vedolizumab Placebo (DRUG).
Who is sponsoring clinical trial NCT02790138?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.